List view / Grid view
A preclinical candidate calcitonin gene-related peptide (CGRP) antagonist has been nominated for advancement into further preclinical studies as an investigational treatment for migraine.
11 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Heptares Therapeutics and Jitsubo have entered into a collaboration to develop peptide candidates designed to target severe gastrointestinal disorders...
29 June 2016 | By Victoria White, Digital Content Producer
Heptares Therapeutics and leadXpro are to employ powerful new approaches for the determination of high-resolution X-ray structures of GPCRs...
25 April 2016 | By Victoria White, Digital Content Producer
Heptares scientists have solved the high-resolution X-ray crystal structures of the GLP-1 (glucagon-like peptide 1) and glucagon receptors...
18 April 2016 | By Victoria White, Digital Content Producer
Heptares and Kymab are to colllaborate to discover, develop and commercialise novel antibody therapeutics targeting a number of GPCRs...
7 April 2016 | By Victoria White, Digital Content Producer
Allergan is to license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development by Heptares...
30 November 2015 | By Victoria White
Heptares and Pfizer have announced they are to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas...
25 November 2015 | By Victoria White
The companies have entered an agreement to discover and develop novel, small-molecule CGRP antagonists for the treatment of migraine...
28 September 2015 | By Victoria White
The $5.5 million grant will support a three-year research project aimed at developing a selective antagonist for the human Orexin-1 receptor...
6 August 2015 | By Victoria White
AstraZeneca and Heptares Therapeutics have entered into a licensing agreement to develop A2A receptor-blocking compounds as cancer immunotherapies...
